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Overview of mitochondrial function
Mitochondria are organelles serving a wide variety of 
actions critical to cellular function, several of which are 
of particular importance to neuronal survival. Th  e 
primary function of mitochondria is to produce energy in 
the form of ATP via oxidative phosphorylation, in which 
electrons are transported down the electron transport 
chain (ETC) while generating a proton gradient. Th  is 
gradient drives ATP synthase [1]. Mitochondrial function 
is particularly important to the central nervous system 
(CNS) since the CNS uses 20% of the body’s resting 
metabolic energy, 95% of which comes in the form of 
ATP [1]. Neuronal ATP is essential to the function of the 
Na+/K+ and Ca2+ ATPases that maintain ion gradients 
[1,2]. Similarly, mitochondria play a prominent role in 
Ca2+ buﬀ  ering by sequestering Ca2+ using ion transporters 
[1-3]. Th  ese actions of mitochondria are especially 
important to neurotransmission as well as synapse 
formation and remodeling [3-5]. However, critical roles 
for mitochondria go beyond ATP production since mito-
chondria also control cell signaling pathways and cell 
survival via apoptosis regulation [6]. Mitochondria are 
now also understood to be dynamic structures that 
undergo ﬁ  ssion and fusion, and the relationships between 
mitochondrial dynamics and other ‘classical’ functions 
are a matter of intense investigation. For these reasons, 
mitochondria are commonly implicated in neuro  degen-
era  tive diseases, including Alzheimer’s disease (AD) and 
Parkinson’s disease (PD).
Several neurodegenerative diseases show alterations in 
mitochondrial DNA (mtDNA) and genes that encode for 
mitochondria respiratory chain subunits [7]. Similarly, 
dysfunction of enzymes involved in mitochondrial res-
pira  tion has been reported in neurodegenerative diseases 
[7,8]. Such deﬁ  cits may lead to generation of excessive 
reactive oxygen species (ROS) and oxidative damage, 
clearly implicated in several neurodegenerative diseases, 
or to depletion of ATP [7,8]. Besides damaging tissues 
directly, ROS are thought to react with the nitric oxide 
(NO) produced by activated microglia, forming reactive 
nitrogen species (RNS) [7]. More recently, it has been 
demonstrated that mitochondrial dynamics likely plays a 
key role in AD and PD as proteins that regulate mito-
chondrial ﬁ  ssion and fusion are altered in some neuro-
degenerative diseases [3,8]. Given the proposed role of 
mitochondrial dysfunction in AD and PD, restoration of 
mitochondrial function is a focus of therapeutic 
development.
Th   is review will concentrate on mitochondrial involve-
ment in AD and PD and emphasize current therapeutics 
that may directly or indirectly target mitochondria 
function. Potential roles of mitochondrial ﬁ  ssion  and 
fusion, at present a major area of active research, in AD 
and PD treatment also will be addressed.
1. Alzheimer’s disease
1.1. Clinical presentation and pathology
AD is the most common neurodegenerative disease, 
contributing up to 70% of all cases of dementia, and has 
an exponentially increasing prevalence after the age of 65 
[9]. Both common late-onset sporadic and rare autosomal 
Abstract
In neurons, mitochondria serve a wide variety of 
processes that are integral to their function and 
survival. It is, therefore, not surprising that evidence 
of mitochondrial dysfunction is observed across 
numerous neurodegenerative diseases. Alzheimer’s 
disease and Parkinson’s disease are two such diseases 
in which aberrant mitochondrial activity is proposed 
to contribute to pathogenesis. Current therapies for 
each disease target various mechanisms, but few, if 
any, directly target improved mitochondrial function. 
Recent discoveries pertaining to mitochondrial 
dynamics reveal that regulation of mitochondrial 
fi  ssion and fusion may play a key role in the 
pathogenesis of these diseases and consequently 
could be novel future therapeutic targets.
© 2010 BioMed Central Ltd
Mitochondrial therapeutics in Alzheimer’s disease 
and Parkinson’s disease
Jake G Hoekstra, Kathleen S Montine, Jing Zhang and Thomas J Montine*
REVIEW
*Correspondence: tmontine@uw.edu
Department of Pathology, University of Washington, 325 9th Avenue, Seattle, 
WA 98104, USA
Hoekstra et al. Alzheimer’s Research & Therapy 2011, 3:21
http://alzres.com/content/3/3/21
© 2011 BioMed Central Ltddominant forms exist [10]. Biomarkers in cerebrospinal 
ﬂ  uid or structural and functional neuroimaging are being 
used to assist in clinical classiﬁ  cation of AD [11]. Patho-
logically, AD is characterized by the presence of neuritic 
plaques and neuroﬁ  brillary tangles, composed primarily 
of amyloid-beta (Aβ) and abnormal tau (respectively), 
which are found predominantly in cerebral cortex and 
other medial temporal lobe structures [9]. It is worth 
noting that, to date, most of the eﬀ  ective AD biomarkers 
are related to Aβ or tau species [11,12]. Th  e earliest 
pathologic event occurring in AD is thought to be 
synapse loss, as several changes in proteins related to 
synaptic vesicles and membranes have been observed in 
AD brains [9,13]. It is hypothesized that soluble Aβ 
oligomers cause synaptic and neuronal dysfunctions that 
then lead to potentially interconnected processes of 
excito toxicity,  neuroinﬂ   ammation, oxidative damage, 
insoluble protein accumulation, and neurodegeneration 
[9,14].
1.2. Mitochondrial involvement in Alzheimer’s disease
Mitochondrial abnormalities have been associated with 
AD. Several enzymes involved in the Krebs cycle and 
ETC, including pyruvate dehydrogenase complex, keto-
glutarate dehydrogenase complex, and cytochrome 
oxidase, are altered in the brains, platelets, and peripheral 
cells of AD patients [15-18]. Isolated mitochondria from 
AD patients also show decreased complex IV activity as 
well as elevated hydrogen peroxide production [19]. 
Indeed, oxidative damage to DNA, proteins, and lipids is 
elevated in AD patients compared with controls [20-22]. 
Aβ has also been linked to mitochondrial dysfunction in 
various studies. Aβ, especially the peptide that is 42 
amino acids long, is toxic to cells in vitro [23] and 
decreases ETC complex IV activity [24]. Aβ or the Aβ 
precursor protein (APP) associates with mitochondria in 
the brains of AD patients, particularly with the trans-
locase of the outer mitochondrial membrane (TOMM) 
40 and the translocase of the inner mitochondrial 
membrane (TIMM) 23, suggesting possible mitochon-
drial translocation [19,25]. When a mutant form of 
human APP is overexpressed in mice, Aβ accumulates in 
mitochondria and, compared with controls, decreases 
Ca2+ buﬀ   ering capacity, complex IV activity, and ATP 
levels and increases ROS production [26]. Two recent 
studies have found that Aβ induces abnormal mito  chon-
drial transport within axons [27,28]. Th  erefore,  elevated 
Aβ might contribute to mitochondrial dysfunction, ROS 
produc  tion, and stress to neurons in AD. An alternative 
hypo  thesis asserts that, in sporadic AD, mitochondrial 
function declines beyond a threshold level to activate a 
pathway yielding the pathologic hallmarks of AD, speciﬁ  -
cally overproduction of Aβ [29]. Th  is would exacer  bate 
mitochondrial dysfunction, leading to a re  inforcing 
destructive cycle [29]. Key ﬁ   ndings that support this 
hypothesis come from the use of cybrids (that is, cells 
with mitochondria derived from another cell). For 
example, mitochondria from ﬁ  broblasts and platelets of 
AD patients show decreased complex IV activity, a 
feature that remains consistent when cybrids are cultured 
over time, leading to elevated Aβ production and 
deposits [29,30].
1.3. Therapeutics and treatment
Current therapies for AD do not directly target mito-
chondria but may act through various mechanisms that 
can aﬀ  ect mitochondria (Table 1). One such mechanism 
is regulation of neuroinﬂ  ammation [7]. When activated, 
microglia produce NO, which can interact with ROS 
(produced by mitochondria as a normal product of ETC 
activity) to generate RNS [7]. ROS and RNS can damage 
mitochondria as well as other organelles, leading to 
decreased ETC function, further ROS production, and 
decreased ATP production, resulting in neuron death [7]. 
Cholinesterase inhibitors such as donepezil, rivastigmine, 
and galantamine, which are approved by the US Food and 
Drug Administration (FDA) for AD treatment, may 
function through this manner as their use decreases 
markers of inﬂ   ammation and improve AD symptoms 
[31,32]. Nonsteroidal anti-inﬂ  ammatory drugs (NSAIDs) 
may decrease inﬂ   ammation in a similar manner, but 
results from observational studies and clinical trials have 
not been consistent [31-33]. Another mechanism is by 
decreasing Ca2+ entry into neurons, as excessive intra-
cellular Ca2+ can cause mitochondrial dysfunction, 
resulting in ATP depletion and excessive ROS generation 
[34]. Blocking Ca2+ inﬂ  ux decreases the amount of intra-
cellular Ca2+ present in neurons, and this would decrease 
ROS generation by mitochondria. N-methyl-D-aspartate 
(NMDA) receptor antagonists (also FDA-approved for 
AD treatment) that suppress Ca2+ channel activity have 
been used with some success in treating AD [31,32]. A 
recent strategy that may aﬀ  ect mitochondria is decreas-
ing Aβ load, and this may be achieved by decreasing Aβ 
production or enhancing its clearance [31,35]. Excessive 
levels of Aβ may be taken up by mitochondria, causing 
decreased complex IV activity, ATP production, and Ca2+ 
buﬀ   ering, resulting in excessive ROS production and 
neuron death [19,23-26]. Aβ immunotherapy is an 
avenue being investigated to treat AD by reducing Aβ 
levels and has yielded some promising results [35]. An 
Aβ vaccine consisting of a synthetic Aβ peptide and an 
immune response booster was developed and tested in 
humans, but its trial was halted because of the develop-
ment of aseptic meningoencephaitis and leuko  encephalo-
pathy (reviewed in [35]). Some follow-up studies indi-
cated changes in biomarkers associated with AD, decreased 
Aβ load in plaques, and (in those who produced anti-Aβ 
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however, others reported that clearance did not prevent 
progressive neurodegeneration [37]. Current trials that 
are in various phases and that use passive immunization 
against Aβ (that is, anti-Aβ antibodies) are being 
evaluated, but further studies are clearly needed [35]. Aβ-
binding alcohol dehydrogenase (ABAD), an enzyme 
present in neuronal mitochondria, has been shown to 
coimmunoprecipitate and colocalize with Aβ in human 
tissue, with increased precipitation in AD patients [38]. 
Data from mouse models of AD support inhibiting Aβ-
ABAD interaction as a possible therapeutic strategy for 
AD [38,39]. Other treatments such as anti  oxidants, 
vitamins, statins, natural products, and hormone therapy 
have been studied but do not give consistent results 
[31-33].
2. Parkinson’s disease
2.1. Clinical presentation and pathology
PD is a progressive neurodegenerative disease with an 
average age of onset of between 55 and 60 years of age 
and a 2% lifetime risk [40]. As with AD cases, a small 
fraction of PD cases (5% to 10%) are due to autosomal 
dominant or recessive forms of disease, whereas the 
majority of PD cases are sporadic [40]. PD is diagnosed 
clinically by a constellation of motor symptoms, including 
resting tremor, rigidity, postural instability, and slowness 
of movement (bradykinesia) [40,41]. Th   e most prominent 
changes in PD are loss of dopamine (DA)-producing 
neurons that project from the substantia nigra pars 
compacta (SNpc) to the striatum [40,41] and accumulation 
of eosinophilic intraneuronal protein inclu  sions called 
Lewy bodies [34,40,41]. Lewy bodies are composed 
primarily of α-synuclein, parkin, ubiquitin, and neuro-
ﬁ  laments [34,41]. Currently, it is thought that one of the 
proximal events leading to DA neuron death is the forma-
tion of α-synuclein ﬁ   brils from misfolded α-synuclein 
[34]. Th  ese ﬁ  brils can continue to aggregate misfolded 
proteins, leading to the formation of larger inclusions 
with the eventual formation of Lewy bodies and ulti-
mately neuron death [34,41].
2.2. Mitochondrial involvement in Parkinson’s disease
Mitochondrial dysfunction has been repeatedly asso-
ciated with PD. Complex I of the ETC is decreased in the 
SNpc of PD patients when compared with controls, 
leading to excessive ROS formation [42]. Oxidative 
damage to lipids, proteins, and nucleic acids is also 
elevated in PD brain tissue [43-45]. Toxicants recapitu-
lating most aspects of human PD also implicate mito-
chon  drial dysfunction in PD pathogenesis, particularly 
through complex I inhibition. Th  ese toxicants include 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
and rotenone [46]. MPTP was discovered when a drug 
abuser who synthesized and injected himself with MPTP-
contaminated meperidine analog presented with 
parkinsonism; this patient later showed damage to the 
DA system in the SNpc at autopsy [47]. Other drug 
abusers subsequently presented with clinical symptoms 
of PD due to MPTP exposure [46]. MPTP is metabolized 
to 1-methy-4-penylpyridium (MPP+), which enters DA 
neurons via the DA transporter. MPP+ binds to and 
inhibits complex I of the ETC, leading to DA neuron 
death and PD symptoms [46]. Rotenone also acts by 
inhibiting complex I. Although rotenone is highly 
lipophilic and can cross the plasma membrane, it causes 
selective DA neuron degeneration with elevated oxidative 
stress, indicating that DA neurons may be particularly 
susceptible to mitochondrial dysfunction [48].
Studies on two genes that are mutated in inherited 
forms of PD, PINK1, and parkin further implicate mito-
chondria in PD. In Drosophila, ablation of either gene 
causes ﬂ   ight muscle degeneration, and mitochondria 
appear enlarged and swollen with fragmented christae 
[49-51]. Whereas parkin expression in a PINK1 knockout 
reverses this phenotype, PINK1 expression in a parkin 
knockout does not, indicating that parkin acts down-
stream of PINK1 to aﬀ   ect mitochondria [49-51]. 
Table 1. Current treatments for Alzheimer’s disease
Therapy Results  Mitochondrial  involvement?
Cholinesterase inhibitors  Improves AD symptoms and decreases markers of  May decrease nitric oxide produced, leading to decreased 
  infl  ammation   RNS and ROS
NMDA receptor antagonists  Improves AD symptoms and decreases ROS production  May decrease amount of ROS produced due to excessive 
   intracellular  Ca2+
Enhanced clearance of Aβ  May improve cognition   May decrease Aβ-induced mitochondrial dysfunction and 
   ROS  generation
NSAIDs  No consistent results   May reduce infl  ammation and ROS
Antioxidants  No consistent results  Can reduce ROS
Herbal/Natural products  No consistent results  Potentially decreases Aβ, infl  ammation, and ROS generation
Aβ, amyloid-beta; AD, Alzheimer’s disease; NMDA, N-methyl-D-aspartate; NSAID, nonsteroidal anti-infl  ammatory drug; RNS, reactive nitrogen species; ROS, reactive 
oxygen species.
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Drosophila also has been observed [51,52] along with 
sensitivity to compounds that model PD and generate 
ROS [49]. One hypothesis is that loss of these PD-related 
genes that help regulate mitochondrial function leads to 
increased sensitivity to neurotoxic insults and DA neuron 
death.
2.3. Therapeutics and treatment
As with AD, a majority of current PD treatments (Table 2) 
do not target the mitochondria directly, although 
mitochondrial protection is more common in PD than 
AD. Th   e current gold standard to restore DA signaling is 
the DA precursor levodopa (L-DOPA), which crosses the 
blood brain barrier, combined with a peripheral 
decarboxylase inhibitor such as carbidopa, which 
minimizes the gastrointestinal and cardiovascular side 
eﬀ   ects of DA [53,54]. Treatment may also include a 
selective inhibitor of monoamine oxidase B (MAO-B) or 
catechol-O-methyltransferase (COMT) to decrease DA 
metabolism [53,54]. DA agonists also have been used but 
appear less eﬀ  ective than L-DOPA [53,54]. Unfortunately, 
the eﬀ  ectiveness of L-DOPA therapy often is limited and 
can be associated with debilitating side eﬀ  ects [54]. L-
DOPA has been hypothesized to enhance neurodegenera-
tion [54] since DA metabolism by MAO-B generates ROS 
[55]. In theory, this oxidative stress would cause 
mitochondrial dysfunction and further ROS production. 
MAO-B inhibitors may decrease the amount of oxidative 
damage potentially caused by DA metabolism [53,54]; 
however, data from some clinical investigations do not 
support this hypothesis [56]. Regulation of Ca2+ inﬂ  ux 
shows a slight eﬀ   ect in alleviating dyskinesia in PD 
patients [53,54]. While regulation of intracellular Ca2+ to 
prevent ROS production is a potential therapeutic target 
in PD, NMDA receptor antagonists that block Ca2+ entry 
have shown minimal beneﬁ  ts in treating PD [53,54]. A 
more promising strategy may be to supplement mito-
chondria with molecules that improve their function. In 
this case, not only would ATP production improve, but 
ROS production by mitochondria might be decreased 
[53,54,57-59]. Coenzyme Q10 and creatine both may act 
through such a mechanism, with Coenzyme Q10 improv-
ing electron ﬂ   ow and creatine improving high-energy 
phosphate reservoirs [53,54,57-59]. Any approach that 
suppresses ROS production might also impact Lewy 
body formation since ROS can modify α-synuclein, 
increasing its tendency to aggregate and possibly form 
Lewy bodies [34,40].
3. Mitochondrial dynamics: new direction of 
mitochondrial research and potential therapeutics
Although mitochondrial dysfunction is extensively asso-
ciated with AD and PD, direct eﬀ  ective mitochondrial 
therapy is very limited. A new area of mitochondrial 
research, known as mitochondrial dynamics, may 
provide new opportunities for mitochondrial therapies in 
AD and PD. Accumulating evidence suggests that 
mitochondrial morphology and transport can be 
regulated by ﬁ   ssion and fusion, with fusion regulated 
primarily by mitofusins (Mfn) 1 and 2 and optic atrophy 
1 (OPA1) and ﬁ   ssion regulated primarily by Fis1 and 
dynamin-related protein 1 (Drp1) [60]. Several obser-
vations support the involvement of mitochondrial 
dynamics in neurodegeneration. Mutations in Mfn2 lead 
to Charcot-Marie-Tooth disease and peripheral neuro-
pathy, and mutations in OPA1 lead to autosomal 
dominant optic atrophy and loss of optic nerve ﬁ  bers 
Table 2. Current treatments for Parkinson’s disease
Therapy Results  Mitochondrial  involvement?
Levadopa and DA agonists  Improves PD symptoms  May improve mitochondrial function in neurons by restoring 
   nigrostriatal  signaling 
MAO-B inhibitors  Blocks oxidative deamination  May improve mitochondrial function in neurons targeted by DA and 
    may decrease ROS produced by mitochondria
COMT inhibitors  Blocks catechol metabolism  May improve mitochondrial function in neurons by restoring 
   nigrostriatal  signaling
Anticholinergic drugs  Most eff  ective in alleviating tremor and rigidity  May improve mitochondrial function in striatal neurons by balancing 
    the DA and acetylcholine
NMDA receptor antagonists  Can suppress dyskinesia  May decrease amount of ROS produced due to excessive intracellular 
   Ca2+
Coenzyme Q10  Less disability develops in patients given  May increase electron fl  ow in electron transport chain and decrease 
 Coenzyme  Q10 compared with placebo in   ROS production
  one study [59] 
Creatine  Not rejected as futile in a phase II futility  May increase high-energy phosphate pool and decrease ROS 
  clinical trial [58]   production
COMT, catechol-O-methyltransferase; DA, dopamine; MAO-B, monoamine oxidase B; NMDA, N-methyl-D-aspartate; PD, Parkinson’s disease; ROS, reactive oxygen 
species.
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levels were shown to be decreased in brain tissue from 
AD patients whereas Fis1 levels were increased [5]. When 
these changes were mimicked in primary neurons using 
RNAi (RNA interference) or gene overexpression, 
mitochondria were decreased in neurites and dendritic 
spines, indicating that such changes may play a role in 
AD [5]. Th   is study also showed that Drp1 overexpression 
in primary cultures protected neurons against neurotoxic 
insult, suggesting that increased fusion may be a 
neuroprotective strategy [5]. In a separate study, Drp1 
was genetically ablated in Drosophila with a resulting loss 
of synaptic mitochondria, perhaps due to defects in 
axonal transport [61], an aspect of neuronal function 
aﬀ   ected in neurodegenerative diseases [62]. Using the 
neuromuscular junction (NMJ) to study synaptic actions 
of Drp1, the same group observed defects in Ca2+ buﬀ  er-
ing and neurotransmission during prolonged stimulation 
of the NMJ [61]. In a study of PINK1 and parkin in 
Drosophila, mitochondrial size and shape and muscle 
degeneration phenotypes observed in knockout Droso-
phila were reversed when Drp1 was overexpressed or 
Mfn2 or OPA1 function was decreased, again showing 
that increased ﬁ   ssion or decreased fusion may be 
protective [50]. Although this is a relatively recent area of 
research, these results suggest that loss of ﬁ  ssion  or 
increased fusion could play a role in AD or PD. A 
proposed connection of mitochondrial ﬁ  ssion and fusion 
to AD and PD is diagrammed in Figure 1. Mitochondrial 
dynamics also may alter mitophagy (elimination of 
dysfunctional mitochondria) [63], a topic beyond the 
scope of this review. Regulating mitochondrial dynamics 
is a new and emerging topic that may provide new targets 
for therapy.
Conclusions
Mitochondrial dysfunction is a feature of AD and PD. 
Mitochondria can aﬀ   ect neuronal function not only 
through ATP production but also through regulation of 
ion homeostasis (especially Ca2+), synapse function, ROS 
generation, cell signaling, and survival. Current therapies 
for AD and PD might inﬂ  uence mitochondrial function 
indirectly, but few speciﬁ   cally target mitochondrial 
function. Regulating mitochondrial dynamics might pro-
vide new targets for mitochondria-directed therapy in 
AD and PD.
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